ValuEngine upgraded shares of HCP (NYSE:HCP) from a hold rating to a buy rating in a research report report published on Monday morning.
A number of other research firms also recently commented on HCP. Royal Bank of Canada raised HCP from a sector perform rating to an outperform rating in a report on Friday, November 2nd. Cantor Fitzgerald boosted their price target on HCP from $29.00 to $30.00 and gave the company an overweight rating in a report on Thursday, November 1st. BMO Capital Markets restated a hold rating and issued a $27.00 price objective on shares of HCP in a research report on Wednesday, October 31st. Morgan Stanley boosted their price objective on HCP from $23.50 to $25.00 and gave the company an equal weight rating in a research report on Thursday, August 16th. Finally, Bank of America boosted their price objective on HCP from $27.50 to $28.00 and gave the company a buy rating in a research report on Monday, September 17th. Three analysts have rated the stock with a sell rating, eight have given a hold rating and six have issued a buy rating to the company. The stock presently has an average rating of Hold and an average target price of $26.75.
Shares of HCP stock traded down $0.04 on Monday, reaching $28.78. 76,686 shares of the stock were exchanged, compared to its average volume of 3,822,521. The company has a quick ratio of 0.48, a current ratio of 0.48 and a debt-to-equity ratio of 1.21. HCP has a twelve month low of $21.48 and a twelve month high of $29.32. The company has a market capitalization of $13.54 billion, a price-to-earnings ratio of 14.76, a price-to-earnings-growth ratio of 7.24 and a beta of 0.16.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, November 20th. Investors of record on Monday, November 5th will be given a dividend of $0.37 per share. This represents a $1.48 annualized dividend and a dividend yield of 5.14%. The ex-dividend date is Friday, November 2nd. HCP’s payout ratio is 75.90%.
Institutional investors and hedge funds have recently modified their holdings of the stock. Security Capital Research & Management Inc. grew its holdings in HCP by 20.2% in the 2nd quarter. Security Capital Research & Management Inc. now owns 12,680,529 shares of the real estate investment trust’s stock valued at $327,411,000 after buying an additional 2,129,250 shares in the last quarter. Daiwa Securities Group Inc. grew its holdings in HCP by 8,304.8% in the 3rd quarter. Daiwa Securities Group Inc. now owns 8,977,168 shares of the real estate investment trust’s stock valued at $236,279,000 after buying an additional 8,870,358 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of HCP by 1.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 7,178,265 shares of the real estate investment trust’s stock valued at $185,341,000 after purchasing an additional 100,296 shares during the last quarter. Resolution Capital Ltd lifted its stake in shares of HCP by 118.1% in the 2nd quarter. Resolution Capital Ltd now owns 6,481,980 shares of the real estate investment trust’s stock valued at $167,365,000 after purchasing an additional 3,509,889 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. lifted its stake in shares of HCP by 5.1% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 5,030,874 shares of the real estate investment trust’s stock valued at $129,898,000 after purchasing an additional 245,207 shares during the last quarter. Hedge funds and other institutional investors own 89.61% of the company’s stock.
HCP Company Profile
HCP, Inc is a fully integrated real estate investment trust (REIT) that invests in real estate serving the healthcare industry in the United States. HCP owns a large-scale portfolio primarily diversified across life science, medical office and senior housing. Recognized as a global leader in sustainability, HCP has been a publicly-traded company since 1985 and was the first healthcare REIT selected to the S&P 500 index.
Featured Article: How to Invest in the Dividend Aristocrat Index
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for HCP Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCP and related companies with MarketBeat.com's FREE daily email newsletter.